InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...

With only two weeks left of U.S. Congress in session, a final push for a consensus on healthcare is underway. Both Democrats and Republicans ...

The trial, conducted in Bangladesh in partnership with the International Centre for Diarrhoeal Disease Research, Bangladesh ...

In the final days of the Biden Administration, the EPA locked in a formaldehyde risk evaluation built on the Agency’s ...

Zero cancellations. The Eras Tour wasn’t just a concert—it was an endurance experiment. Here’s the wellness blueprint Swift used to stay strong, injury-free, and astonishingly consistent.

The convergence of disease threats, including Covid, flu, RSV and norovirus threatens to overwhelm hospitals, disrupt ...

Rep. Gus Bilirakis, a Palm Harbor Republican who chairs the House Commerce, Manufacturing and Trade Subcommittee, introduced ...

The denim case reveals the deeper moral collapse of Bangladesh's economic system. In compassionate capitalism, the 60/40 structure supports social trust, innovation, and reinvestment. In Bangladesh, ...

On December 3, 2025, the U.S. Environmental Protection Agency (EPA) announced the availability of and solicited public comment on an Updated Draft Risk Calculation Memorandum (Draft Memorandum) to ...

Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...

The veterans disability system has traditionally been a sacred cow for politicians of all stripes. Now, as part of the conservative war on the Department of Veterans Affairs, the administration is ...

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...